Loading patent…
AssigneesAgenus Inc., Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center
InventorsMarc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Roberta Zappasodi, Rikke Baek Holmgaard, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
Estimating the term…
Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination.
A method of increasing T cell activation in a subject that has cancer, the method comprising administering to the subject an effective amount of a therapeutic combination comprising a first isolated antibody that specifically binds to human CTLA-4 and a second isolated antibody that specifically binds to human PD-1, wherein:
A method of increasing T cell activation in a subject that has cervical cancer, the method comprising administering to the subject an effective amount of a therapeutic combination comprising a first isolated antibody that specifically binds to human CTLA-4 and a second isolated antibody that specifically binds to human PD-1, wherein:
Dependencies are inferred from the claim text.